e21005 Background: Effect of PDL1 on OS in patients with MAC is controversial. This relationship has not been studied systematically in U.S. midwestern population, a largely homogenous Caucasian group. We examined the effect of PDL1 expression on OS in MAC pts at ILCC, one of the largest practices in U.S. Midwest. Methods: We conducted a retrospective analysis of all MAC pts who presented at ILCC in 2018. PDL1 status was defined as high if PDL1 was ≥50%, low if 1≤50% & -ve if 0≤1%. High and low groups together were called +. Statistical analysis was performed using the log rank Kaplan Meier method. Results: Results were available in 104/125 pts [83%]. 68/104 pts [65%] received anti PDL1 antibodies Nivolumab, Pembrolizumab, Durvalumab, & Atezolizumab. 43/68 pts were PDL1+ and 25/68 were -ve. Median OS of PDL1+ high exp was 10.78 months [m] & of low exp was 9.7 m. There was no statistical difference in OS in these groups [p = 0.984778]. We also evaluated this relationship between all PDL1+ pts [high and low expressers together] and PDL1- ve pts. We did not find any difference between these groups either. Median OS of all PDL1+ was 9.77 m & PDL1 -ve was 6.67 m [p = 0.435038]. Conclusions: Our study suggests that OS of MAC in our pt population is not influenced by PDL1 status. The potential influence of patient ethnic, genetic & molecular biomarker traits on OS needs to be explored further.[Table: see text]